| __timestamp | Axsome Therapeutics, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 17268000 |
| Thursday, January 1, 2015 | 2419289 | 19667000 |
| Friday, January 1, 2016 | 6343648 | 27823000 |
| Sunday, January 1, 2017 | 7206691 | 36468000 |
| Monday, January 1, 2018 | 9351522 | 31282000 |
| Tuesday, January 1, 2019 | 13598030 | 39610000 |
| Wednesday, January 1, 2020 | 28896749 | 52820000 |
| Friday, January 1, 2021 | 66646205 | 96803000 |
| Saturday, January 1, 2022 | 159253661 | 177977000 |
| Sunday, January 1, 2023 | 323123000 | 173612000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Cytokinetics, Incorporated and Axsome Therapeutics, Inc. have demonstrated contrasting trends in their SG&A efficiency.
From 2014 to 2023, Axsome Therapeutics saw a staggering increase in SG&A expenses, growing by over 23,000% from 1.4 million to 323 million. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Cytokinetics experienced a more moderate increase of around 900%, reaching 174 million in 2023.
While Axsome's rapid growth in expenses may indicate a robust expansion strategy, Cytokinetics' steadier rise suggests a more controlled approach. Investors and stakeholders should consider these trends when evaluating the companies' long-term strategic positions.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?